HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Autor: Milana A. Bergamino, Elena López-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C.U. Cheang, Abigail Evans, Adrian Ball, Akhil Johri, Ali Nejim, Alison Jones, Allan Corder, Amanda Thorne, Ambika Anand, Amitabha Chakrabarti, Anne Robinson, Anupam Modi, Ashraf Patel, Ashutosh Kothari, Brendan McFall, Caroline Mortimer, Caroline Lee, Charlie Chan, Charlotte Abson, Christopher Holcombe, Christopher Hinton, Ciaran Hollywood, Claire Murphy, Clare Crowley, Claudia Harding-Mackean, Clive Griffith, Conrad Lewanski, Daniel Rea, David Hwang, Derek Crawford, Dinesh Thekkinkattil, Douglas Ferguson, Douglas Adamson, Duncan Wheatley, Duraisamy Ravichandran, Ed Babu, Elaine Hyett, Fawzia Ashkanani, Fiona Hoar, Frances Kenny, Gary Dyke, Geoffrey Sparrow, null Gilbert, Giles Cunnick, Hafiz Algurafi, Helen Sweetland, Highes-Davies Prof, Hisham Hamed, Ian Smith, Ian Laidlaw, Ilyas Khattak, Jacqueline Newby, Jacqueline Rees-Lee, Jalal Kokan, Jane Barrett, Jay Dolatrai Naik, Jayant Vaidya, Jennifer Forrest, Jitendra Parmar, Jocelyn Adams, John Fox, Jonathan Roberts, Jonathan Dawson, Julie Doughty, Jull Donnelly, Kathleen Dunn, Kian Chin, Kieran Horgan, Kislaya Thakur, Ludger Barthelmes, Lynda Wyld, Madhumita Bhattacharyya, Maher Hadaki, Makam Kishore, Marcus Ornstein, Maria Bramley, Maria Bews-Hair, Marina Parton, Mark Sibbering, Mark Kissin, Mark Churn, Martin Hogg, Mary Quigley, Matthew Hatton, Matthew Winter, Matthew Adelekan, Michael Shere, Michael Carr, Michael Williams, Mohammed Absar, Muhammad Sharif, Muireann Kelleher, Nawaz Walji, Nicholas Williams, Nicholas Gallegos, Nigel Bundred, Olivia Hatcher, Perric Crellin, Peter Crane, Peter Donnelly, Peter Kneeshaw, Philip Walker, Prakash Sinha, Pudhupalayam Bhaskar, Racheal Soulsby, Radha Todd, Raghavan Vidya, Rakesh Mehra, Ramachandran Prasad, Ramsay Cutress, Ravi Sharma, Rebecca Roylance, Rebecca Goranova, Reem Ramzi Salman, Riccardo Bonom, Richard Johnson, Richard Sutton, Rick Linforth, Rob Coleman, Robert Grieve, Robert Leonard, Robert Reichert, Robert Kennedy, Roshan Agarwal, Rozenn Allerton, Russell Burcombe, Ruth Davis, Sankaran Narayanan, Sankaran Chandrasekharan, Sarah Vesty, Seema Seetharam, Serena Ledwidge, Shabana Iqbal, Shamaela Wahee, Shobha Silva, Simon Pain, Simon Holt, Simon Thomson, Simon Smith, Simon Ellenbogen, Siobhan Laws, Stephen Chan, Stephen Johnston, Steve Holt, Steven Thrush, Stuart McIntosh, Sumohan Chatterjee, Susan Cleator, Tamoor Usman, Tayo Johnson, Tibor Kovacs, Tracey Irvine, Urmila Barthkur, Vanessa Pope, Victoria Alexandra Brown, Vummiti Muralikrishna, Walid Samra, William Maxwell, Zoe Winters

Publikováno v: EBioMedicine. 83

Background: oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f2c36f0affe9cade26299ca49ee96f2
https://pubmed.ncbi.nlm.nih.gov/35985932

Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis

Autor: Andrew Elders, Pawana Sharma, C Mulatero, John Ford, Radha Todd, Robert Jones, Fiona Stewart, Pamela Royle, Graham Mowatt

Publikováno v: European Journal of Cancer. 49:416-430

Aim To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid tumours and, using a network meta-analysis, indirectly compare denosumab with bisphosphonates and best supportive care. Data sources MEDLINE (1948 to A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efb588ed860ef2e97aacfb7a8490d67a
https://doi.org/10.1016/j.ejca.2012.07.016

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype

Autor: Stan B. Kaye, James Carmichael, Richard L Hayward, Paul Mitchell, Caroline O. Michie, Timothy A. Yap, Nicholas S. Reed, Kalpana Ragupathy, Melanie Mackean, Jan Lubinski, Michelle Ferguson, Jan H.M. Schellens, Russell D. Petty, Radha Todd, Sharon Harden, James Paul, Tzyvia Rye, Patricia Roxburgh, Charlie Gourley

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(15)

Purpose To compare the frequency of visceral relapse of BRCA1/2-deficient ovarian cancer to that of nonhereditary controls. Patients and Methods All patients diagnosed in Scotland with epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb11cba4f8b95b41b7b96389960f6ab2
https://pubmed.ncbi.nlm.nih.gov/20406939

Alterations and Interdependence in Self-Reported Sleep-Wake Parameters of Patient–Caregiver Dyads During Adjuvant Chemotherapy for Breast Cancer.

Autor: Kotronoulas, Grigorios¹ g.kotronoulas@surrey.ac.uk, Wengström, Yvonne², Kearney, Nora³

Publikováno v: Oncology Nursing Forum. May2016, Vol. 43 Issue 3, p288-301. 14p. 6 Charts, 1 Graph.

Abstract P1-08-28: Real world use of OncotypeDx testing in the management of breast cancer. The North East England experience

Autor: Abigail Gault, Jayshree Veeratterapillay, Wendy Taylor

Publikováno v: Cancer Research. 82:P1-08

OncotypeDx testing is now routinely used to help decide management of hormone positive HER2 negative breast cancer. We have reviewed adjuvant treatment and long-term outcomes of breast cancer patients in those who had a genomic OncotypeDx study perfo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf6ecece59835c59283c960bcfe51962
https://doi.org/10.1158/1538-7445.sabcs21-p1-08-28